SA
Go ProLog In
CRVS
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
13 analysts·Moderate coverage
73
Score
12 Buy (92%)1 Hold (8%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1292%
Hold
18%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$27.00
+119.3%
Consensus
$31.00
+151.8%
Bull
$42.00
+241.2%
12-Month Target Range13 analysts
$27.00$31.00$42.00
Current $12.31Consensus
Current Price
$12.31
Upside to Consensus
$18.69

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev—
EPS—
FY2028
Rev+424.72%
EPS—
FY2029
Rev+132.44%
EPS—

Earnings Surprises

Recent Analyst Actions

Apr 17, 2026Goldman Sachs
Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs
Target:$40.00
+166.0%from $15.04
Jan 29, 2026Mizuho Securities
Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho
Target:$30.00
+46.1%from $20.54
Jan 22, 2026Jefferies
Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies
Target:$42.00
+62.8%from $25.80
Jan 21, 2026Oppenheimer
Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer
Target:$32.00
+42.0%from $22.54
Jan 20, 2026Barclays
Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays
Target:$28.00
+30.8%from $21.41
Jan 20, 2026Mizuho Securities
Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho
Target:$20.00
+2.5%from $19.52
Jan 20, 2026H.C. Wainwright
Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright
Target:$27.00
+48.2%from $18.22
Oct 29, 2025Mizuho Securities
Corvus Pharmaceuticals price target raised to $13 from $11 at Mizuho
Target:$13.00
+72.1%from $7.55
Oct 13, 2025Barclays
Corvus Pharmaceuticals initiated with an Overweight at Barclays
Target:$16.00
+130.9%from $6.93
May 20, 2025Mizuho Securities
Corvus Pharmaceuticals price target lowered to $11 from $12 at Mizuho
Target:$11.00
+198.9%from $3.68
Nov 13, 2024Jefferies
Corvus Pharmaceuticals (CRVS) PT Raised to $13 at Jefferies
Target:$13.00
+227.5%from $3.97
Oct 22, 2024Mizuho Securities
Mizuho Upgrades Corvus Pharmaceuticals (CRVS) to Outperform
Target:$12.00
+58.7%from $7.56
Aug 18, 2023Oppenheimer
Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer
Target:$7.00
+219.6%from $2.19

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance